Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)

Introduction Proteasome inhibition is an established therapy for many malignancies. Carfilzomib, a novel proteasome inhibitor, was combined with irinotecan to provide a synergistic approach in relapsed, irinotecan-sensitive cancers. Materials and Methods Patients with relapsed irinotecan-sensitive c...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Susanne M., Chansky, Kari, Leggas, Markos, Thompson, Michael A., Villano, John L., Hamm, John, Sanborn, Rachel E., Weiss, Glen J., Chatta, Gurkamal, Baggstrom, Maria Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577369/
https://www.ncbi.nlm.nih.gov/pubmed/28204981
http://dx.doi.org/10.1007/s10637-017-0441-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577369/
https://www.ncbi.nlm.nih.gov/pubmed/28204981
http://dx.doi.org/10.1007/s10637-017-0441-4

Ejemplares similares